IP Library Granted Patent US 8,853,370
Granted Patent B2
US 8,853,370 · App. 13/546,293 · Granted Oct 7, 2014

Plant-produced glycoprotein comprising human-type sugar chain

Inventors: Tatsuji Seki (Osaka, JP); Kazuhito Fujiyama (Osaka, JP)
Assignee: Phyton Holdings, LLC
C12N9/0065C12Y111/01007C12N15/8257C12Y204/01038C12P21/005C12N15/8245C12N15/8242C12N9/1051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,853,370
App. No.
13/546,293
Granted
Oct 7, 2014
Kind
B2
Abstract

The present invention provides a method for manufacturing a glycoprotein having a human-type sugar chain comprising a step in which transformed plant cell is obtained by introducing to a plant cell the gene of glycosyltransfetase and the gene of an exogenous glycoprotein, and a step in which the obtained transformed plant cell is cultivated.

Claims (19)

1. A plant-produced glycoprotein, comprising (i) a galactosylated sugar chain that comprises a galactose residue linked to a N-acetylglucosamine residue in β1,4-linkage, and (ii) a non-galactosylated sugar chain comprising a xylose residue linked to a mannose residue in β1,2-linkage.

2. The plant-produced glycoprotein of claim 1 , wherein no α1,3-fucose, and/or no β1,2-xylose is linked to the galactosylated sugar chain.

3. The plant-produced glycoprotein of claim 1 , wherein the glycoprotein comprises N-glycans of M7A, M7B, M6B, M3X, M5, GalGNM3, and GalGNM5, wherein M is mannose, X is xylose, Gal is galactose, and N is N-acetylglucosamine, and wherein the structures of M7A, M7B, M6B, M3X, M5, GalGNM3, and GalGNM5 are set forth in FIG. 1 .

4. The plant-produced glycoprotein of claim 1 , wherein the plant-produced glycoprotein is an enzyme, a hormone, a cytokine, an antibody, a vaccine antigen, a receptor, or a serum protein.

5. The plant-produced glycoprotein of claim 4 , wherein the plant-produced glycoprotein is an enzyme selected from the group consisting of horseradish peroxidase, kinase, glucocerebrosidase, α-galactosidase, tissue-type plasminogen activator (TPA), and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

6. The plant-produced glycoprotein of claim 4 , wherein the plant-produced glycoprotein is selected from the group consisting of enkephalin, interferon-alpha, granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), chorion stimulating hormone, interleukin-2, interferon-beta, interferon-gamma, erythropoietin, vascular endothelial growth factor, human choriogonadotropin (HCG), leuteinizing hormone (LH), thyroid stimulating hormone (TSH), prolactin, and ovary stimulating hormone.

7. The plant-produced glycoprotein of claim 4 , wherein the plant-produced glycoprotein is an antibody.

8. The plant-produced glycoprotein of claim 1 , wherein the galactose residue is a terminal sugar residue in the galactosylated sugar chain.

9. The plant-produced glycoprotein of claim 1 , wherein the plant-produced glycoprotein is produced by a process comprising:

cultivating a transformed plant cell comprising a first gene encoding a galactosyltranferase, and a second gene encoding the glycoprotein under conditions allowing expression of the galactosyltransferase and the glycoprotein; wherein the transformed plant cell further comprises one or more genes encoding one or more of N-acetylglucosaminyl-transferase I, mannosidase I, and mannosidase II; and

isolating the glycoprotein, which comprises a human-type sugar chain comprising a galactose residue linked to a N-acetylglucosamine residue, wherein addition of the galactose residue is catalyzed by the galactosyltransferase.

10. The plant-produced glycoprotein of claim 9 , wherein no α1,3-fucose, nor and/or no β1,2-xylose is linked to the galactosylated sugar chain.

11. The plant-produced glycoprotein of claim 9 , wherein the glycoprotein comprises N-glycans of M7A, M7B, M6B, M3X, M5, GalGNM3, and GalGNM5, wherein M is mannose, X is xylose, Gal is galactose, and N is N-acetylglucosamine, and wherein the structures of M7A, M7B, M6B, M3X, M5, GalGNM3, and GalGNM5 are set forth in FIG. 15 .

12. The plant-produced glycoprotein of claim 9 , wherein glycoprotein is an enzyme, a hormone, a cytokine, an antibody, a vaccine antigen, a receptor, or a serum protein.

13. The plant-produced glycoprotein of claim 12 , wherein the plant-produced glycoprotein is an enzyme selected from the group consisting of horseradish peroxidase, kinase, glucocerebrosidase, α-galactosidase, tissue-type plasminogen activator (TPA), and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

14. The plant-produced glycoprotein of claim 12 , wherein the plant-produced glycoprotein is selected from the group consisting of enkephalin, interferon-alpha, granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (C-CSF), chorion stimulating hormone, interleukin-2, interferon-beta, interferon-gamma, erythropoietin, vascular endothelial growth factor, human choriogonadotropin (HCG), leuteinizing hormone (LH), thyroid stimulating hormone (TSH), prolactin, and ovary stimulating hormone.

15. The plant-produced glycoprotein of claim 12 , wherein the plant-produced glycoprotein is an antibody.

16. The plant-produced glycoprotein of claim 9 , wherein the first gene encodes a galactosyltransferase comprising the amino acid sequence of SEQ ID NO:6.

17. The plant-produced glycoprotein of claim 13 , wherein the first gene comprises the nucleotide sequence of SEQ ID NO:5.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2012
From: THE DOW CHEMICAL COMPANY
To: DFB BIOTECH, INC.
Reel/Frame 029489/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2012
From: SEKI, TATSUJI; FUJIYAMA, KAZUHITO
To: THE DOW CHEMICAL COMPANY
Reel/Frame 029489/0671 →
CHANGE OF NAME Recorded Dec 18, 2012
From: PHYTON, INC.
To: PHYTON HOLDINGS, INC.
Reel/Frame 029490/0524 →
CHANGE OF NAME Recorded Dec 18, 2012
From: DFB BIOTECH, INC.
To: PHYTON, INC.
Reel/Frame 029490/0532 →
Priority Claims (1)
JP 10-350584 · Dec 9, 1998 · national
Continuity (5)
Continuation 12795316 · Jun 7, 2010
Continuation 11810567 · Jun 6, 2007
Continuation 10870635 · Jun 17, 2004
Division 09857651
Related Publication 20130040391A1 · Feb 14, 2013